During the recent session, Applied Dna Sciences Inc (NASDAQ:APDN)’s traded shares were 0.68 million, with the beta value of the company hitting 0.74. At the last check today, the stock’s price was $1.97, reflecting an intraday loss of -4.37% or -$0.09. The 52-week high for the APDN share is $460.00, that puts it down -23250.25 from that peak though still a striking 15.23% gain since the share price plummeted to a 52-week low of $1.67. The company’s market capitalization is $2.17M, and the average intraday trading volume over the past 10 days was 4.24 million shares, and the average trade volume was 766.56K shares over the past three months.
Applied Dna Sciences Inc (APDN) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 3.00. APDN has a Sell rating from 0 analyst(s) out of 1 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 1 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -3.0.
Applied Dna Sciences Inc (NASDAQ:APDN) trade information
Applied Dna Sciences Inc (APDN) registered a -4.37% downside in the last session and has traded in the green over the past 5 sessions. The stock plummet -4.37% in intraday trading to $1.97, hitting a weekly high. The stock’s 5-day price performance is 2.07%, and it has moved by -72.64% in 30 days. Based on these gigs, the overall price performance for the year is -99.59%. The short interest in Applied Dna Sciences Inc (NASDAQ:APDN) is 0.23 million shares and it means that shorts have 2.06 day(s) to cover.
The consensus price target of analysts on Wall Street is $1.5, which implies a decrease of -31.33% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $1.5 and $1.5 respectively. As a result, APDN is trading at a premium of 23.86% off the target high and 23.86% off the low.
Applied Dna Sciences Inc (APDN) estimates and forecasts
In the rating firms’ projections, revenue will increase 53.99% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 1.19M as predicted by 1 analyst(s). Meanwhile, a consensus of 1 analyst(s) estimates revenue growth to 1.28M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 929.63k and 797.52k respectively. In this case, analysts expect current quarter sales to grow by 27.47% and then jump by 60.00% in the coming quarter.
APDN Dividends
Applied Dna Sciences Inc is due to release its next quarterly earnings on 2025-Feb-12. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Applied Dna Sciences Inc (NASDAQ:APDN)’s Major holders
Applied Dna Sciences Inc insiders own 19.47% of total outstanding shares while institutional holders control 26.90%, with the float percentage being 33.41%. MATHER GROUP, LLC. is the largest shareholder of the company, while 29.0 institutions own stock in it. As of 2024-06-30, the company held over 700.0 shares (or 0.0803% of all shares), a total value of $287.0 in shares.
Also, the Mutual Funds coming in first place with the largest holdings of Applied Dna Sciences Inc (APDN) shares are Fidelity Concord Street Trust-Fidelity Extended Market Index Fund and Fidelity Concord Street Trust-Fidelity Series Total Market Index Fund. Data provided on Dec 31, 2024 indicates that Fidelity Concord Street Trust-Fidelity Extended Market Index Fund owns about 5.74 shares. This amounts to just over 0.01 percent of the company’s overall shares, with a $11337.0 market value. The same data shows that the other fund manager holds slightly less at 1.06, or about 0.00% of the stock, which is worth about $2092.0.
